Frontage Laboratories acquires Concord Biosciences: ‘Committed to build a global CRO’

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/pichet_w)
(Image: Getty/pichet_w)
Frontage Laboratories has acquired Concord Biosciences, taking a “significant step” towards the company’s goal of building a global organization, says CEO.

Frontage Laboratories Inc. is a full-service early-stage contract research organization (CRO) with locations in the US and China. Last week the Exton, PA-headquartered company announced its acquisition of Concord Biosciences.

Previously under the name Ricerca Biosciences LLC, Concord Biosciences is a preclinical CRO located on a 20-acre campus near Cleveland, OH. The company conducts drug safety, metabolism, bioanalytical, residue and environmental fate studies.

Dr. Song Li, founder and CEO of Frontage Laboratories, said the acquisition is a “significant step”​ toward reaching the company’s goal of building a global CRO with integrated services.

“The addition of Concord Bio to the Frontage family will enable us to provide pharmaceutical product development services from lead selection to IND-enabling studies to commercialization,” ​he said in a press release. “Additionally, the agrochemical expertise of Concord Bio will position Frontage as a major CRO in the agricultural products industry."

Frontage Laboratories has not responded to a request for comment.

Related news

Show more

Related products

show more

Using SDTM, ADaM, and SEND

Using SDTM, ADaM, and SEND

Formedix | 09-Nov-2022 | Technical / White Paper

This article gives an overview of SDTM, ADaM, SEND and ARM, and discusses how these CDISC standards fit in with the wider clinical trial process, and how...

How to design an effective CRF

How to design an effective CRF

Formedix | 10-Oct-2022 | Technical / White Paper

CRFs and eCRFs are used for gathering patient data during clinical trials. They play a crucial role in helping to assess the safety and efficacy of clinical...

The Complexities of Ophthalmic Drug Development

The Complexities of Ophthalmic Drug Development

Altasciences | 04-Oct-2022 | Technical / White Paper

Ophthalmic drug development comes with a unique set of challenges that can be mitigated by working with an end-to-end solution provider with regulatory...

Related suppliers

Follow us

Products

View more

Webinars